Gentian Diagnostics ASA

Remuneration Information • Aug 2, 2018

Grant of share options

Grant of share options

Moss, 02.08.18

Reference is made to the stock exchange release of 14 May 2018 in which the Board of Directors decided to launch a share option programme of up to 559,852 options. On 2 August 2018 the following employees was granted options in Gentian Diagnostics AS as follows:

Hilja Ibert, CEO of Gentian Diagnostics AS: 139,963 options. Number of options after the grant is 139,963 and number of shares are nil.

Njaal Kind, Group CFO of Gentian Diagnostics AS: 34,991 options. Number of options after the grant is 34,991 and number of shares are nil.

The exercise price for the options granted is NOK 65.24 being the average volume-weighted share price on the Oslo Stock Exchange for the past 10 trading days prior to today.

The right to exercise the options is vested over a period of 3 years, with 1/3 of the options vesting by the end of each year as follows:

(i) 1/3 of the options granted, no earlier than 2 years after the allocation date

(ii) 1/3 of the options granted, no earlier than 3 years after the allocation date

(iii) 1/3 of the options granted, no earlier than 4 years after the allocation date

For further information, please contact:

Tomas Settevik, Chairman Cell: +47 90 79 48 25